Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TAK, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Vedolizumab FDA approved May 2014 · Entyvio |
Colitis, Ulcerative | Phase 4 · NCT04259138 | Completed |
| Maribavir FDA approved Nov 2021 · Livtencity |
Cytomegalovirus (CMV) | Phase 3 · NCT06439342 | Completed |
| Mezagitamab | Immune Thrombocytopenic Purpura (ITP) | Phase 3 · NCT06948318 | Recruiting |
| TDV | Dengue Fever | Phase 3 · NCT06579755 | Active not recruiting |
| Therapeutic Immune Globulin | Primary Immunodeficiency Diseases (PID) | Phase 2/3 · NCT05755035 | Completed |
| TAK-360 | Idiopathic Hypersomnia | Phase 2/3 · NCT07646678 | Recruiting |
| Soticlestat | Lennox Gastaut Syndrome (LGS) | Phase 3 · NCT04938427 | Completed |
| Zasocitinib | Psoriatic Arthritis | Phase 3 · NCT07286058 | Recruiting |
| Vonicog Alfa | Von Willebrand Disease (VWD) | Phase 3 · NCT05582993 | Recruiting |
| Active Comparator: 6.0mg GRI-0621 | Psoriatic Arthritis | Phase 3 · NCT06671483 | Recruiting |
| ADVATE | Von Willebrand Disease (VWD) | Phase 3 · NCT05582993 | Recruiting |
| Elritercept | Myelodysplastic Syndrome | Phase 3 · NCT07422480 | Recruiting |
| IGI, 10% | Multiple Myeloma | Phase 3 · NCT06980480 | Recruiting |
| Chemotherapy Agents | Leukemia | Phase 1/2 · NCT05886491 | Terminated |
| EGFR/CD3-targeting T-cell Engaging Molec | Squamous Cell Cancer of Head and Neck (SCCHN) | Phase 1/2 · NCT04844073 | Terminated |
| Anti-CCR8 Antibody-drug Conjugate TAK-18 | Advanced or Metastatic Solid Tumors | Phase 1/2 · NCT07205718 | Recruiting |
Also used in these trials (approved or third-party drugs, not TAK's own candidates): Tofacitinib, Adalimumab, Ustekinumab, Epoetin Alfa, Azacitidine, Venetoclax, Rifampin, Mefenamic Acid, Itraconazole, Alprazolam.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TAK holds $461B in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TAK files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TAK and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →